Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
Arsela Prelaj, Achille Bottiglieri, Claudia Proto, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Giulia Galli, Alessandro De Toma, Giuseppe Viscardi, Marta Brambilla, Riccardo Lobefaro, Federico Nichetti, Sara Manglaviti, Mario Occhipinti, Alice Labianca, Monica Ganzinelli, Rosaria Gallucci, Nicoletta Zilembo, Gabriella Greco, Valter Torri, Filippo de Braud, Marina Chiara Garassino
Topics & Concepts
MedicineRashExpanded accessInternal medicineOncologyClinical endpointLung cancerProgressive diseaseExonnon-small cell lung cancer (NSCLC)Response Evaluation Criteria in Solid TumorsGastroenterologyChemotherapyClinical trialBiochemistryGeneA549 cellChemistryLung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchMelanoma and MAPK Pathways